Market Cap | 15.31M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -23.94M | Forward P/E | -0.29 | EPS next Y | - | 50D Avg Chg | 19.00% |
Sales | 162k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -15.00% |
Dividend | N/A | Price/Book | 1.97 | EPS next 5Y | 20.00% | 52W High Chg | -77.00% |
Recommedations | 3.00 | Quick Ratio | 0.29 | Shares Outstanding | 5.41M | 52W Low Chg | 49.00% |
Insider Own | 39.31% | ROA | -29.42% | Shares Float | 2.96M | Beta | 7.84 |
Inst Own | 7.21% | ROE | - | Shares Shorted/Prior | 36.60K/37.06K | Price | 2.83 |
Gross Margin | -111.11% | Profit Margin | - | Avg. Volume | 27,880 | Target Price | - |
Oper. Margin | -10,491.49% | Earnings Date | Nov 11 | Volume | 4,406 | Change | 2.89% |
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Cherington Charles | Director Director | Dec 02 | Buy | 3.28 | 261,756 | 858,560 | 556,465 | 12/06/22 |
Singer Nicholas Jason | Director Director | Dec 02 | Buy | 3.28 | 283,286 | 929,178 | 266,214 | 12/06/22 |
DENNY GEORGE P III | 10% Owner 10% Owner | Aug 20 | Sell | 16.06 | 75,000 | 1,204,500 | 4,775,117 | 08/20/21 |
DENNY GEORGE P III | 10% Owner 10% Owner | Aug 20 | Buy | 13.48 | 3 | 40 | 3 | 08/20/21 |